Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial

Meplazumab, a humanized CD147 antibody, has shown favourable safety and efficacy in our previous clinical studies. In DEFLECT (NCT04586153), 167 patients with severe COVID-19 were enroled and randomized to receive three dosages of meplazumab and a placebo. Meplazumab at 0.12 mg/kg, compared to the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Bian, Huijie, Chen, Liang, Zheng, Zhao-Hui, Sun, Xiu-Xuan, Geng, Jie-Jie, Chen, Ruo, Wang, Ke, Yang, Xu, Chen, Shi-Rui, Chen, Si-Yu, Xie, Rong-Hua, Zhang, Kui, Miao, Jin-Lin, Jia, Jun-Feng, Tang, Hao, Liu, Shuang-Shuang, Shi, Hong-Wei, Yang, Yong, Chen, Xiao-Chun, Malhotra, Vinay, Nasir, Nosheen, Khanum, Iffat, Mahmood, Faisal, Hamid, Saeed, Stadnik, Claudio Marcel Berdun, Itinose, Kengi, de Oliveira, Caroline Cândida Carvalho, Dusilek, Cesar, Rivabem, Lucas, Cavalcante, Adilson Joaquim Westheimer, Lopes, Suzara Souto, Saporito, Wladmir Faustino, Fucci, Fábio José Concilio, Simon-Campos, Jesus Abraham, Wang, Ling, Liu, Lin-Na, Wang, Qing-Yi, Wei, Ding, Zhang, Zheng, Chen, Zhi-Nan, Zhu, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885411/
https://www.ncbi.nlm.nih.gov/pubmed/36717539
http://dx.doi.org/10.1038/s41392-023-01323-9

Ejemplares similares

Ejemplares similares